Navigation Links
EDS Returns to Georgia With $391 Million Medicaid Win
Date:4/29/2008

Peach state contracts EDS interChange System to manage nation's

eighth-largest Medicaid program New IT solution will administer payments to health care providers, enable electronic health records, help state identify health trends and verify

Medicaid eligibility

ATLANTA, April 29 /PRNewswire-FirstCall/ -- EDS, the recognized leader in providing health care support to state governments, has been awarded a seven-year, $391 million contract by the state of Georgia to design, develop and implement a new-generation Medicaid Management Information System (MMIS). The new system will provide fiscal agent and enrollment broker services and establish electronic health records (EHRs) for Medicaid recipients. The contract was awarded in the first quarter of 2008.

The EDS Georgia interChange system will provide the platform to support delivery of fiscal agent services to Georgia's 45,000 Medicaid providers, who annually care for more than 1.2 million beneficiaries. Georgia operates the nation's eighth-largest Medicaid program in the nation.

The contract returns EDS to Georgia as the state's fiscal agent after a five-year hiatus and brings to 22 the number of states for which EDS serves as fiscal agent or principal IT provider. EDS previously served as the state's fiscal agent from 1986-2003.

EDS will implement its federally certified interChange Medicaid system, which has served as an industry model and is in operation or being implemented in more than a dozen states.

In addition to providing claims processing for health care providers and enabling EHRs for Medicaid recipients, the Web-based system will provide Georgia with greater flexibility. It also will provide the state with data analysis about health care trends and outcomes of Georgia's Medicaid population to assess needs and impacts of current programs. Additionally, the system will help the state identify potential fraud
'/>"/>

SOURCE Electronic Data Systems Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. USA TODAY Weight-Loss Challenge Returns For 5th Year With Eight Weeks of Compelling Stories and Online Features
2. Fred Hutchinson Cancer Research Centers Big Expedition for Cancer Research Team Returns From Reconnaissance Flight Over Alaskas Glacier Bay Park
3. ORBIS Internationals Flying Eye Hospital Returns to Myanmar
4. Study Shows New Therapy Opens Blocked Fallopian Tubes, Returns Fertility Without Surgery
5. Speaking of Womens Health Community Event Returns to All Wal-Mart Supercenters Nationwide January 12th
6. Fitness Sensation Susan Powter Returns to Her Legions of Fans and Followers with Focus on Whole Body Wellness Program
7. BET Networks Award-Winning Rap-It-Up HIV/AIDS Campaign Returns to New York City for The Youth Empowerment Tour on November 13-16
8. American Pacific Director, Fred D. Gibson, Jr., Continues Funding Georgia Tech Endowment
9. Prevent Child Abuse Georgia Appoints New CEO
10. Georgia Kids Kick Butts on April 2
11. Wellness Initiative for 2008 Tour de Georgia Presented by AT&T Led by New Partnership With Blue Cross and Blue Shield of Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ELHI, India, Dec. 5 He...zation today launched a global partnership to subs...ccurate and affordable alternatives. , , Th...h Asian Conference on Alternatives to Mercury in H...tions and the Indian NGO Toxics Link. , , "...
(Date:12/4/2008)... CEO marks 10th anniversary of drive to eliminate ...lionth albendazole tablet and grant to The Carter ... In a meeting today with ...nter, Jimmy Carter, as well as global health thoug...(LSE/NYSE: GSK ) announced that it has made a $2...
(Date:12/4/2008)...UKEE, Dec. 4 Aurora Health Care is...amin D supplements. Aurora,s Care Management,Clin...o educate all Aurora,caregivers about the benefit...owing evidence that higher Vitamin D levels may im...steoporosis, certain muscle conditions and,season...
(Date:12/4/2008)...RBOR, Mich., Dec. 4 BAPTIST HEALTH...., and the state,s largest health system, has,exp... Thomson Reuters -- a,solution that enabled the s...,interventions and save more than $1 million. , ...tle Rock campus show that,CareFocus prompts appro...
Breaking Medicine News(10 mins):Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3
...ssor of animal science and microbiology and molecu...te University found that a new cell// line has the...s is good news because it would result in the prod...s which is cheaper and produced in a shorter perio...
..., differences in the treatment given to male and f...ms persist, a new study has found//. In all, the ...nefit from hospitals' quality-improvement measures... the drugs, tests, and counseling about smoking, d...
...ns have succumbed to chikun gunya at Kandamanur vi... members of each family have been affected by the .../ Demanding that the government take immediate st..., vice chairperson of Mayuladumparai panchayat uni...
...g the tissue abnormalities, or lesions, that typic...men infected with multiple genotypes// of the huma...ccording to a study published in the July issue of...evention. Although doctors have known that the ce...
Other Medicine News:Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 3Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: